These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32334364)

  • 21. Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation.
    Marchand M; Fuseau E; Critchley DJ
    J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):99-118. PubMed ID: 20084538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience.
    Thome-Souza S; Kadish NE; Ramgopal S; Sánchez Fernández I; Bergin AM; Bolton J; Harini C; Libenson M; Olson H; Peters J; Poduri A; Rotenberg A; Takeoka M; Kothare SV; Kapur K; Bourgeois BF; Loddenkemper T
    Epilepsia; 2014 Aug; 55(8):1235-44. PubMed ID: 25070475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome.
    McCormack PL
    Pharmacoeconomics; 2012 Mar; 30(3):247-56. PubMed ID: 22332960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treating Lennox-Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide.
    Gresham J; Eiland LS; Chung AM
    Neuropsychiatr Dis Treat; 2010 Oct; 6():639-45. PubMed ID: 20957124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aggravation of atonic seizures by rufinamide: A case report.
    Bektaş G; Çalışkan M; Aydın A; Pembegül Yıldız E; Tatlı B; Aydınlı N; Özmen M
    Brain Dev; 2016 Aug; 38(7):654-7. PubMed ID: 26906013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox-Gastaut Syndrome.
    Kessler SK; McCarthy A; Cnaan A; Dlugos DJ
    Epilepsy Res; 2015 May; 112():18-26. PubMed ID: 25847334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of add-on lacosamide in children with Lennox-Gastaut syndrome.
    Grosso S; Coppola G; Cusmai R; Parisi P; Spalice A; Foligno S; Verrotti A; Balestri P
    Acta Neurol Scand; 2014 Jun; 129(6):420-4. PubMed ID: 24479878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rufinamide efficacy and safety as adjunctive treatment in children with focal drug resistant epilepsy: the first Italian prospective study.
    Moavero R; Cusmai R; Specchio N; Fusco L; Capuano A; Curatolo P; Vigevano F
    Epilepsy Res; 2012 Nov; 102(1-2):94-9. PubMed ID: 22677424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rufinamide for refractory focal seizures: an open-label, multicenter European study.
    Coppola G; Zamponi N; Kluger G; Mueller A; Anna Rita M; Parisi P; Isone C; Santoro E; Curatolo P; Verrotti A
    Seizure; 2013 Jan; 22(1):33-6. PubMed ID: 23079159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Short-term efficacy and safety of rufinamide for Lennox-Gastaut syndrome].
    Takayama R; Fukumura S; Minagawa K; Watanabe T
    No To Hattatsu; 2016 Sep; 48(5):322-6. PubMed ID: 30010275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview.
    Wier HA; Cerna A; So TY
    Paediatr Drugs; 2011 Apr; 13(2):97-106. PubMed ID: 21351809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive, adaptive, and behavioral effects of adjunctive rufinamide in Lennox-Gastaut syndrome: A prospective observational clinical study.
    Operto FF; Verrotti A; Marrelli A; Ciuffini R; Coppola G; Pastorino GMG; Striano P; Sole M; Zucca C; Manfredi V; Città S; Elia M
    Epilepsy Behav; 2020 Nov; 112():107445. PubMed ID: 32920379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study.
    Arzimanoglou A; Ferreira JA; Satlin A; Mendes S; Williams B; Critchley D; Schuck E; Hussein Z; Kumar D; Dhadda S; Bibbiani F
    Eur J Paediatr Neurol; 2016 May; 20(3):393-402. PubMed ID: 26805435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brivaracetam as add-on therapy in children with developmental epileptic encephalopathies: A study of 42 patients.
    Caraballo RH; Reyes G; Chacón S; Fortini PS
    Epilepsy Behav; 2024 Jan; 150():109561. PubMed ID: 38070405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proposed anti-seizure medication combinations with rufinamide in the treatment of Lennox-Gastaut syndrome: Narrative review and expert opinion.
    Sankar R; Chez M; Pina-Garza JE; Dixon-Salazar T; Flamini JR; Hyslop A; McGoldrick P; Millichap JJ; Resnick T; Rho JM; Wolf S
    Seizure; 2023 Aug; 110():42-57. PubMed ID: 37321047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK.
    Benedict A; Verdian L; Maclaine G
    Pharmacoeconomics; 2010; 28(3):185-99. PubMed ID: 20151724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years.
    Conry JA; Ng YT; Kernitsky L; Mitchell WG; Veidemanis R; Drummond R; Isojarvi J; Lee D; Paolicchi JM;
    Epilepsia; 2014 Apr; 55(4):558-67. PubMed ID: 24580023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.
    Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J
    Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with Lennox-Gastaut syndrome: Final results from randomized study 303.
    Arzimanoglou A; Ferreira J; Satlin A; Olhaye O; Kumar D; Dhadda S; Bibbiani F
    Eur J Paediatr Neurol; 2019 Jan; 23(1):126-135. PubMed ID: 30309816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.